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IFN = interferon; IL = interleukin; MIP = macrophage inflammatory protein; RANTES = regulated on activation, normal T cell expressed and
secreted; RSV = respiratory syncytial virus; rVV = recombinant vaccinia virus; Th = T-helper; TNF = tumor necrosis factor.
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Introduction
The World Health Organization estimates that approxi-
mately 14 million people die each year from infections that
are transmitted via the respiratory tract, most of which
occur in childhood. Viral infections of the respiratory tract
are particularly serious during infancy, and viral bronchioli-
tis is the most common cause of infantile hospitalization in
the developed world [1]. It has been estimated to cause
91,000 admissions per year in the USA, with associated
hospitalization costs of $300,000,000 per year. Respira-
tory syncytial virus (RSV) accounts for approximately 70%
of all cases of viral bronchiolitis [2].
RSV bronchiolitis usually affects children under 1 year old,
with a peak incidence at age 2–4 months [3]. During this
period of development, the lungs are growing rapidly and
undergoing alveolar septation. Bronchiolitis may cause
severe insult to the lungs during this critical period, and
might cause long-term effects by delaying or preventing
normal postnatal pulmonary changes. This could result in
smaller lungs in later life that are more susceptible to
disease. Alternatively, neonatal infection may cause long-
lasting changes in host immunity [4].
A recent study [5] showed that infants who experience
RSV bronchiolitis are more likely to develop wheezing and
asthma later in life (Fig. 1). This paper reviews the basic
mechanisms of RSV infection, with particular reference to
links between early RSV infection and the development of
later respiratory symptoms and disease.
Viral bronchiolitis is the most common cause of hospitalization in infants under 6 months of age, and
70% of all cases of bronchiolitis are caused by respiratory syncytial virus (RSV). Early RSV infection
is associated with respiratory problems such as asthma and wheezing later in life. RSV infection is
usually spread by contaminated secretions and infects the upper then lower respiratory tracts.
Infected cells release proinflammatory cytokines and chemokines, including IL-1, tumor necrosis
factor-α, IL-6, and IL-8. These activate other cells and recruit inflammatory cells, including
macrophages, neutrophils, eosinophils, and T lymphocytes, into the airway wall and surrounding
tissues. The pattern of cytokine production by T lymphocytes can be biased toward ‘T-helper-1’ or
‘T-helper-2’ cytokines, depending on the local immunologic environment, infection history, and host
genetics. T-helper-1 responses are generally efficient in antiviral defense, but young infants have an
inherent bias toward T-helper-2 responses. The ideal intervention for RSV infection would be
preventive, but the options are currently limited. Vaccines based on protein subunits, live attenuated
strains of RSV, DNA vaccines, and synthetic peptides are being developed; passive antibody therapy
is at present impractical in otherwise healthy children. Effective vaccines for use in neonates continue
to be elusive but simply delaying infection beyond the first 6 months of life might reduce the delayed
morbidity associated with infantile disease.
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Mechanism of respiratory syncytial virus
infection
RSV belongs to the paramyxovirus family. It is transmitted
by respiratory secretions and by direct contact with conta-
minated surfaces or materials. The most common way in
which RSV is spread is by direct hand-to-hand contact.
Infection occurs when the virus replicates in the tissue.
Epithelial cells are the main target cells for respiratory
viruses, but alveolar macrophages can also be infected.
Infection begins by binding to specific receptors on the
surface of the host cell, followed by internalization and
uncoating. The viral RNA core is then released into the
cytoplasm of the host cell, where it replicates and is trans-
lated by the host cell machinery into viral particles. Viral
assembly occurs in the cytoplasm and at the cell surface,
after which virions are released from the cell. Released
virions then infect other respiratory epithelial cells.
RSV was originally thought to be restricted to the respira-
tory tract, but recent studies have demonstrated viral RNA
in peripheral blood cells during acute infection. It has been
suggested that peripheral virus is not viable but data
suggest it may be able to replicate [6]. In cattle, RSV
appears able to persist in local B lymphocytes [7].
Immune response to respiratory syncytial
virus infection
Infected epithelial cells and alveolar macrophages activate
the immune system’s defenses. The cells release
chemokines, proinflammatory cytokines, and mediators
that include IL-1, tumor necrosis factor (TNF)-α, IL-6, IL-8,
macrophage inflammatory protein (MIP)-1α and RANTES
(regulated on activation, normal T cell expressed and
secreted). Elevated levels of IL-6, IL-8, TNF-α [8], and IL-
11 [9] have been found in nasal lavage fluid of children
with acute upper respiratory infections. These cytokines
and chemokines contribute to airway inflammation and
bronchial hyperresponsiveness, as well as to mucus
hypersecretion and sneezing.
Production of multiple cytokines and chemokines induces
ingress into the airway of diverse inflammatory cells and
their activation. IL-8 secretion causes influx of neutrophils,
which are present in nasal secretions of children with rhi-
novirus upper respiratory infections [10] and in bronchial
secretions of children with RSV infection [11]. RANTES
and MIP-1α are potent chemokines for eosinophils.
Increased levels of RANTES and MIP-1α have been found
in the nasal aspirates of children with virus-induced
asthma exacerbations [12] and in lower airway secretions
of infants with RSV bronchiolitis who are given ventilatory
support [13]. The viral inflammatory response includes
activation of cytotoxic T cells. Virus-specific cellular cyto-
toxic activity has been demonstrated in infants with acute
RSV infection [14]. Once in the airway, recruited cells
prolong inflammation by releasing further cytokines and
chemokines that attract and upregulate other inflammatory
cells.
T-helper (Th) cells are found in the airways of individuals
with RSV infection [15]. T cells produce proinflammatory
mediators that include type 1 cytokines or type 2
cytokines. Th1 cells secrete IL-2, IFN-γ, and lymphotoxin,
whereas Th2 cells secrete IL-4, -5, -6, and -10. IL-4 and
IL-5 promote IgE production and eosinophilia [16]. These
types of T-helper lymphocytes are selectively promoted,
depending on the cytokine environment that is present
during priming (largely determined by innate immune
responses, site, concentration of antigen, and infection
history). The balance between Th1 and Th2 responses is
important in coordinating the protective and immuno-
pathogenic responses to viral infection [17,18]. The
immune system undergoes rapid development prenatally
and during the first months of postnatal life. Infants show a
greater propensity to develop Th2 responses than do
older children.
Antibody responses
In the newborn, passively acquired maternal immunoglobu-
lin appears to protect against infection. This may be the
reason why children under 8 weeks of age are rarely
infected with RSV. Maternal antibody concentration
decreases during the first 6 months of life, leaving infants
between the ages of 2 and 4 months unprotected against
infection. RSV bronchiolitis is most common in children
younger than 6 months old. More than two decades ago,
studies showed that infants with the highest titers of
transplacentally acquired RSV-specific IgG developed less
severe RSV pneumonia and had fewer infections than did
infants with lower titers [19]. Other studies suggest that
Figure 1
Association between bronchiolitis during infancy and wheezing or
asthma in childhood. Infants who experience RSV bronchiolitis are
more likely to develop wheezing and asthma at 1, 3, and 7 years of age
than are matched controls who did not experience bronchiolitis as
infants [5].
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passively acquired maternal antibody suppresses the
development of the infant’s own immune response [20,21].
Local mucosal B cells can produce IgA, the predominant
immunoglobulin in respiratory secretions. IgE interacts
with mast cells causing mediator release, which may con-
tribute to airway narrowing, obstruction, and wheezing.
Welliver et al. [22] observed increased RSV-specific IgE
in nasal secretions of wheezing children with acute RSV
infection, but other groups have not been able to confirm
that finding.
Animal studies
The mouse model of RSV disease is well characterized
and has given rise to a wealth of immunologic information
regarding antiviral defense and immunopathogenic mech-
anisms [23]. Virus replication peaks on day 4 or 5 after
mice are exposed to the pathogen, and cultivable virus is
cleared between days 7 and 9. However, PCR for viral
RNA is still positive for up to 100 days or more after infec-
tion. In terms of the cellular immune response, infected
mice show few changes for the first 3 days, but on day 4
lymphocytes start to be recruited to the airway epithelium.
Natural killer cells are initially abundant in bronchoalveolar
lavage fluid and produce IFN-γ. Over the next few days
these cells are replaced by Th1 CD4+ and CD8+ cells,
which also produce predominantly IFN-γ during primary
infection of unvaccinated animals.
The cytokines produced determine the predominant type
of pathology observed [24]. Openshaw et al. [25]
reported that early IFN-γ production is a key controlling
element of Th1/2 balance during subsequent infection
(Fig. 2). Without IFN-γ a Th2 cytokine profile persists,
which leads to lung eosinophilia. Priming with the major
RSV surface glycoprotein G expressed in a vaccinia virus
vector (recombinant vaccinia virus [rVV]-G) fails to stimu-
late IFN-γ production by infiltrating cells during pulmonary
challenge, leading to Th2 cytokine production and to lung
eosinophilia. In mice primed with rVV expressing the
fusion protein F, Th1 cells produce IFN-γ, inhibiting lung
eosinophilia.
As stated above, in the absence of IFN-γ the Th2
response persists. Th2 cells produce IL-4 and IL-5; the
latter is associated with delayed hypersensitivity and
causes lung eosinophilia [26]. When this response occurs
in infants, it permits the establishment of the Th2 response
as part of T cell memory, which is long lasting.
The immunologic response may also be determined by
genetic factors. In different strains of mice, RSV infected
animals exhibited different Th1 or Th2 responses [27].
Hence, the pathogenesis of bronchiolitis inevitably varies
between species and between individuals with different
genetic and environmental backgrounds.
Delayed effects of respiratory syncytial virus
infection
A recent study found that T-cell activation (as measured
by plasma levels of soluble serum IL-2 receptor, sCD25)
was elevated for 5 months after infantile bronchiolitis,
regardless of severity [28]; this is in marked contrast to
the rapid normalization of soluble IL-2 receptor levels in
other acute viral infections. Such studies suggest that
effects from RSV infections may be responsible for respi-
ratory problems later in life. Increased respiratory symp-
toms have been noted in children who have recovered
from RSV bronchiolitis, and this association lasts for
8–13 years [29,30]. Sigurs et al. [31] followed 47 chil-
dren treated for RSV bronchiolitis as infants for 3 years
and subsequently for 7–8 years [5]. Compared with con-
trols, the RSV-infected patients had a higher rate of
asthma diagnosis (23% versus 1%) and reductions in
measurements of airflow; no differences in lung size were
observed. Noble et al. [32] reported similar findings in 61
patients followed for 9.5 years after hospital admission for
bronchiolitis. Compared with controls, children who had
been treated for bronchiolitis had a higher frequency of
cough and wheeze, and increased bronchodilator use. In
another study, persistent wheeze at the age of 7–8 years
was directly related to the level of RSV-specific IgE
Available online http://respiratory-research.com/content/3/S1/S15
Figure 2
Production of lung eosinophilia in the mouse model of respiratory
syncytial virus (RSV). Lung eosinophilia is linked to the inability of the
major surface glycoprotein G of RSV (RSV G-protein) to stimulate
T-helper (Th)1, or CD8+, cells to produce IFN-γ. Once activated, Th1
cells stimulate macrophages and dendritic cells to produce IL-12. This
induces natural killer (NK) cells and Th1 cells to produce IFN-γ. In the
presence of IFN-γ lung eosinophilia is inhibited; in its absence the Th2
response persists. Th2 cells produce IL-4 and IL-5, which causes lung
eosinophilia. Adapted with permission from Openshaw et al. [25]. 
rVV, recombinant vaccinia virus.
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measured in the nasopharyngeal secretions during the
initial illness, which occurred during the first 6 months of
life [33]. No change in lung function was reported at
7–8 years of age. Similarly, peripheral blood eosinophilia
at the time of acute bronchiolitis was found to predict
wheezing at 7 years of age [34].
From data obtained in mouse experiments, it was hypothe-
sized that initial RSV infection increased Th2 sensitization
to subsequent respiratory infections and to inhaled
antigen. To test this hypothesis, IL-4 and IFN-γ production,
and proliferative responses to RSV antigens and nonviral
allergens was measured in peripheral blood cells of 7- and
8-year-old children [5]. RSV-specific enhancement of IL-4
production was found in children with a history of bronchi-
olitis, whereas all exposed children (regardless of the
severity of first infection) showed good IFN-γ responses
[35]. This finding is in agreement with studies by Teran et
al. [36], who reported asthmatic exacerbations following
viral infection altered cytokine responses.
Animal studies generally support the idea that there is a
direct causal link between RSV infection and delayed
wheezing disease. In guinea pigs, RSV infection causes
increased sensitivity to inhaled histamine for at least
6 weeks [37]. Brown Norway rats develop chronic,
episodic, and reversible airway obstruction after bronchi-
olitis [38]. This condition is produced by a Th2 response
with reduced IFN-γ production. In cattle, viral persistence
in B cells has been demonstrated [7].
If the initial RSV infection causes permanent damage to
the epithelium, cilia, or lung structure, then it may be easier
for antigens to penetrate the lung [6]. In addition, clear-
ance of material from the lung may be impaired. These
factors may leave the lung vulnerable to later colonization
with a nonviral pathogen that could have delayed effects
or cause secondary infection. Other possible mechanisms
for the delayed effect are virus chronicity, persistence or
latency [4,39], and immunologic tolerance [23].
Two hypotheses have been suggested [40,41] to explain
this phenomenon (Fig. 3). The first is that early viral infec-
tions directly damage the developing lung or alter host
immunity, and result in recurrent respiratory symptoms and
subsequent airway dysfunction. The second hypothesis is
that initial respiratory infection unmasks an inherent sus-
ceptibility to long-term respiratory problems. Both of these
factors may contribute to delayed respiratory problems in
some individuals, and are not mutually exclusive.
Conclusion
If early RSV infection causes delayed respiratory problems,
then prevention or delay of neonatal infection is highly
desirable (Table 1). Delaying RSV infection would allow the
lungs to mature and the immune system to develop and
protect infants against sequelae caused by viral chronicity
or persistence, a ‘hitchhiking’ pathogen, lung remodeling,
immunologic memory, and bystander sensitization. Prevent-
ing RSV infections would not alter delayed effects of previ-
ously small lungs or genetic predisposition.
The long-term results of studies of passive or active immu-
nization against RSV disease are therefore keenly awaited.
New studies are underway that aim to determine how
immune-specific responses can be directed to Th1 or Th2,
in the hope that stimulating Th1 responses during the first
exposure will be beneficial and reduce the long-term
sequelae of natural RSV infection.
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Figure 3
Delayed effects of acute respiratory syncytial virus (RSV) infection:
possible mechanisms. The link between RSV infection and delayed
respiratory problems may be explained by a severe initial infection,
which either alters the host lungs or immunity, leading to future
wheeze, or reveals an underlying tendency to wheeze. Adapted with
permission from Balfour-Lynn and Openshaw [41].
Table 1
Challenges for effective treatment and vaccination of
respiratory syncytial virus
Aim
Prevent RSV bronchiolitis in infants under 6 months:
Maternal of neonatal vaccination
Passive antibody administration
Studies are required:
To identify factors that induce Th1 versus Th2 responses
To gain an understanding of tolerance and immune suppression
To gain an understanding the role of nonprotein antigens
To control IgE responses
To boost IgA responses
To make practical improvements to DNA vaccination
To develop new adjuvants
RSV, respiratory syncytial virus; Th, T-helper.
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Progress is being made with vaccines based on viral sub-
units, live attenuated strains of RSV, DNA vaccines, and
synthetic peptides [42–44]. In ongoing clinical trials, vac-
cination of breast-feeding women appears to protect
neonates from RSV infection during the critical first few
months of life [45]. The results indicate the presence of
RSV-specific antibody in breast milk is not associated with
adverse effects on neonatal or infant immune responses to
RSV, but more studies are underway.
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